- Adjusted operating expenses were slightly down from the prior quarter.
- Cash balance was $963 million at the end of June, increasing to approximately $1 billion by end of July after follow-on offering proceeds and Gilead upfront payment.
- Cash runway extended into the second half of 2028.
- G&A expenses were $17.6 million, with $7.4 million non-cash stock-based compensation; adjusted cash G&A increased 6% sequentially.
- Kymera reported Q2 2025 revenue of $11.5 million, all from the Sanofi collaboration.
- R&D expenses were $78.4 million, including $8 million of non-cash stock-based compensation, reflecting a 3% decrease in adjusted cash R&D spend from Q1 2025.
Related items and other data are not available for this feed item.
Dafinchi